Dabigatran vs P-glycoprotein/ABCB1 Inhibitors

Interacting Drugs
Dabigatran
vs
P-glycoprotein/ABCB1 Inhibitors
Security Level
Moderate, Consider therapy modification
Mechanism
P-glycoprotein/ABCB1 Inhibitors: May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.
Management
Dabigatran dose reductions may be needed. According to Canadian labeling, dabigatran dose for prevention of venous thromboembolism post hip or knee replacement should be reduced to 150 mg/day in patients receiving amiodarone, verapamil, or quinidine.

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Dabigatran vs P-glycoprotein/ABCB1 Inhibitors